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Abstract  10 
Background 11 
Successful antimicrobial stewardship interventions are imperative in today’s environment of 12 
antimicrobial resistance. New antimicrobial stewardship interventions should include 13 
qualitative analysis such as a process evaluation to determine which elements within an 14 
intervention are effective and provide insight into the context in which the intervention is 15 
introduced.  16 
Objective  17 
To assess the implementation process and explore the contextual factors which influenced 18 
implementation. 19 
Setting  20 
An academic teaching hospital in Cork, Ireland.  21 
Methods 22 
A process evaluation was conducted on completion of a feasibility study of the introduction 23 
of a procalcitonin antimicrobial stewardship intervention. The process evaluation consisted 24 
of semi-structured face-to-face interviews of key stakeholders including participating 25 
(senior) doctors (5), medical laboratory scientists (3) and a hospital administrator. The 26 
Consolidated Framework for Implementation Research was used to guide data collection, 27 
analysis, and interpretation. 28 
Main outcome measures  29 
Qualitative assessment of the intervention implementation process, the contextual factors 30 
which influenced implementation and identification of improvements to the intervention 31 
and its implementation and determine if proceeding to a randomised controlled trial would 32 
be appropriate. 33 
Results 34 
Analysis of the interviews identified three main themes. (i) The procalcitonin intervention 35 
and implementation process was viewed positively to support prescribing decisions. 36 
Participants identified modifications to procalcitonin processing and availability to improve 37 
implementation and allow procalcitonin to be “more of a clinical influence”. 38 
ii) In the antimicrobial stewardship context the concept of fear of missing an infection and 39 
risks of potentially serious outcomes for patients emerged.  40 
(iii)The hospital context consisted of barriers such as available resources and facilitators 41 
including the hospital culture of quality improvement. 42 
Conclusion 43 
This process evaluation provides a detailed analysis of the implementation of procalcitonin 44 
testing as an antimicrobial stewardship intervention. The positive findings of this process 45 
evaluation and feasibility study should be built upon and a full randomised controlled trial 46 
and economic evaluation should be conducted in a variety of hospital settings to confirm the 47 
effectiveness of procalcitonin as an antimicrobial stewardship intervention.  48 
Impact on practice 49 
• Procalcitonin is a useful additional antimicrobial stewardship intervention 50 
• The fear of missing infections and the risk of negative clinical outcomes for patients 51 
significantly influences antimicrobial prescribing decisions and must be considered 52 
when designing antimicrobial stewardship interventions. 53 
• A culture of quality improvement within a hospital is an important facilitator of 54 
antimicrobial stewardship programmes 55 
 56 
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Introduction 63 
Antimicrobial resistance(AMR) is a significant risk to human health and we face the very real 64 
possibility of a “post antibiotic era in which common infections could once again kill”[1]. 65 
Antimicrobial stewardship(AMS) programmes are well established and include interventions 66 
to improve antimicrobial prescribing[2-4]. Some AMS interventions can lack sustainability[5] 67 
which may be related to contextual factors of those interventions, but these have been poorly 68 
investigated particularly their role in the effectiveness of interventions and sustainability on 69 
a larger scale[6]. This has prompted the suggestion that interventions should look to include 70 
components that enhance enablement for the implementation of evidence-based practice,[6] 71 
defined as “increasing means or reducing barriers to increase capability or opportunity”[6, 7].  72 
Furthermore a recent Cochrane review of interventions to improve antimicrobial prescribing 73 
for hospital patients[8] has advocated for greater use of qualitative research such as a process 74 
evaluation(PE) of a trial to determine which elements within an intervention are effective.  75 
A qualitative PE[9] assesses the fidelity and quality of implementation, providing insight into 76 
the context into which the intervention is introduced, clarifies causal mechanisms of the 77 
intervention without assuming that the intervention itself leads to the outcome and builds 78 
the evidence base to support the intervention that will inform policy makers and practice[10]. 79 
A PE is important in complex interventions in the healthcare setting as a means to identify the 80 
underlying cause of the success or failure of interventions because occasionally even highly 81 
successful quality improvement interventions[11] have proven difficult to replicate in 82 
different contexts due to fundamental differences in how the intervention was delivered[12]. 83 
A PE is an important element of implementation research and should incorporate a 84 
theoretical framework to guide data collection, analysis and interpretation. Theoretical 85 
frameworks have a predictive capacity to identify or explain causal mechanisms of 86 
implementation. This allows for identification of contextual factors that influenced 87 
implementation and so aids our ability to generalise study findings.[13]. 88 
Greater utilisation of rapid diagnostic tests and biomarkers has been highlighted as an 89 
important factor in addressing AMR  by improving infection diagnosis, supporting prescribing 90 
decisions and AMS programmes[14]. Procalcitonin is a biomarker which has been shown to 91 
support prescribing decisions and reduce antimicrobial use safely in patients with respiratory 92 
tract infections[15-18].  The findings of a recent Cochrane review[17] supports its use in the 93 
context of AMS in safely reducing antimicrobial consumption by 2.4 days in patients with 94 
respiratory tract infections. We have previously reported the positive influence of 95 
procalcitonin on antimicrobial prescribing following the introduction of procalcitonin testing 96 
in a feasibility study[19]. The study identified some variability in the use and interpretation of 97 
procalcitonin levels suggesting a range of factors influenced implementation and should be 98 
explored to improve the effectiveness of intervention implementation in the future.  99 
Feasibility studies should be complemented by a qualitative PE[9] to facilitate improved 100 
development and implementation of interventions[20]. This is particularly relevant when 101 
introducing new diagnostic tests to support AMS to assess how best to use such new tests[21] 102 
and reporting of qualitative analysis of procalcitonin implementation has been limited[22, 103 
23].  104 
Aim of the study 105 
To explore how and why the introduction of a procalcitonin intervention worked or did not 106 
work in an Irish hospital setting. The study objectives were to gain an understanding and 107 
assessment of the fidelity and quality of the implementation process, explore the contextual 108 
factors which influenced implementation, identify the barriers and facilitators to 109 
implementation and inform improvements to the intervention and its implementation if 110 
proceeding to a randomised controlled trial was deemed appropriate. 111 
Ethics 112 
The study was approved by the Clinical Research Ethics Committee of University College Cork 113 
and the Cork Teaching Hospitals (reference code ECM 4 (w) and ECM 3 (III)). Written informed 114 
consent was obtained from all participants prior to the interviews and confidentiality of the 115 
participants was assured. 116 
Methods 117 
The Standards for Reporting Qualitative Research were used to guide the development of 118 
this manuscript[24]. 119 
A qualitative PE was conducted of a single centre, randomised, open-label feasibility study[19] 120 
of the introduction of procalcitonin testing in patients admitted to hospital with a lower 121 
respiratory tract infection, under the care of the respiratory medicine team, during on-call 122 
acute unselected general medical take. The feasibility study ran from June 1st 2017 to May 123 
31st 2018 and was conducted in a single, 321 bed model 3 (smaller general)[25] inner city, 124 
voluntary acute University Teaching Hospital, which is part of the South/South West Hospital 125 
Group[26] in the Republic of Ireland. The PE was conducted following completion of the 126 
feasibility study.   127 
The Consolidated Framework for Implementation Research(CFIR) [27] was used to guide data 128 
collection, analysis, and interpretation.  It is a meta-theoretical framework based on existing 129 
determinant frameworks and multiple implementation theories which provides a roadmap of 130 
constructs to monitor the implementation process[27] by recognising that implementation is 131 
a multidimensional phenomenon with multiple interacting influences from the individual to 132 
the organisation and beyond[28]. The CFIR  was chosen because it can be applied at any stage 133 
of the evaluation process of an intervention, it provides a framework to investigate and assess 134 
the complex multi-level nature of implementation in the healthcare setting including barriers 135 
and facilitators to effective intervention implementation[13] and provides a way in which to 136 
organise and communicate findings. 137 
Participants 138 
An invitation to participate in the study was issued in person or by email to key stakeholders 139 
involved in the feasibility study or would be involved in the decision to implement 140 
procalcitonin testing in the hospital in the future. All agreed to participate but one medical 141 
doctor later withdrew due to scheduling constraints. Participants included five medical 142 
doctors (DR1-5) (3 respiratory clinicians and 2 general clinicians), three medical laboratory 143 
scientists (MS1-3) and a hospital administrator (ADM). The interviews ranged in length from 144 
6 to 29 minutes with a mean duration of 16 minutes. 145 
Data collection 146 
Semi-structured face-to-face interviews were conducted by the primary researcher. 147 
Interviews took places in the hospital where the study was conducted at a date and time that 148 
was convenient for participants. The interview topic guide was developed by two researchers 149 
(FOR and AF), both pharmacists with experience of AMS. The interview topic guide was 150 
informed by the most relevant CFIR  constructs[27] which were used as a ‘check-list’ of 151 
variables for consideration. The topic guide was refined following a pilot interview with a 152 
medical doctor who participated in the feasibility study. Pilot interview data were included in 153 
the study due to the limited number of medical doctors participating directly in the feasibility 154 
study.  155 
Interviews with medical laboratory scientists focused on the provision of procalcitonin testing 156 
in the laboratory, the interviews with doctors focused on the use of procalcitonin in making 157 
antimicrobial prescribing decisions while the interviews of participants with managerial 158 
responsibilities and the hospital administrator focused on implementation of procalcitonin 159 
testing on a larger, ongoing scale in the hospital. Issues and opinions on AMS and the hospital 160 
context for change and quality improvement were asked of all participants. 161 
All interviews were digitally recorded and transcribed verbatim by a professional transcription 162 
service. The accuracy and quality of the transcripts was checked against the original 163 
recordings and any identifiable data was removed from the transcripts (by FOR). 164 
Data analysis 165 
Interview analysis used the framework method[29, 30] which provides a systematic step-wise 166 
approach to produce structured outputs of summarised data and is most commonly used for 167 
the thematic analysis of semi-structured interview transcripts[29]. It consists of the following 168 
steps 1. Transcription of the interviews, 2. Familiarisation with the interview data 3. Coding 169 
of the data using the CFIR constructs as deductive codes (open coding was applied when 170 
themes emerged during the familiarisation process that did not fit within the definitions of 171 
the CFIR constructs) 4. Charting and indexing of the data using a thematic framework 5. 172 
Interpretation and analysis of the data.  173 
The interview transcripts were coded independently by two researchers (FOR and AF) using 174 
the CFIR constructs and open coding by thematic analysis. All 39 constructs of the CFIR were 175 
used as the a priori codebook for this qualitative study. Important domains and constructs 176 
were identified based on the frequency of their appearance in the interviews, the degree of 177 
importance articulated by the participants or the researchers, or both. Emergent themes 178 
were reviewed throughout the interview process and the team made an assessment as to 179 
when data saturation had occurred. All authors reviewed the final codes. Discrepancies were 180 
resolved through discussion.   181 
Results 182 
Nine interviews were conducted with hospital staff to explore the different aspects of the 183 
procalcitonin intervention implementation in the hospital setting. Participants roles in 184 
implementation are contained in Table 1 below.  The results have been informed by the CFIR 185 
and are categorised into three themes. 1. The procalcitonin intervention and the 186 
implementation process, 2. The AMS/AMR context and 3. The hospital/organisational 187 
context. Within these themes participants described a range of factors that interact with each 188 
other and the intervention to produce an effect as a facilitator or barrier to implementation. 189 
The CFIR constructs identified in the themes are listed in Table 2 below. They are supported 190 
by qualitative excerpts from the interviews (Tables S1, S2 and S3 available as supplementary 191 
data). The constructs of the CFIR are highlighted in bold in the text.  192 
Theme 1: Procalcitonin intervention and implementation process 193 
Participants described the procalcitonin intervention as having a well-established evidence 194 
base to support its use and clinical situations where it could act as an “extra marker” to 195 
support antimicrobial prescribing decisions. These decisions require clinicians to balance the 196 
need to adequately treat patients while also safely minimising antibiotic exposure and is a 197 
situation where “procalcitonin would actually play a very useful role.” The feasibility study 198 
design and accompanying PE aligned with the trialability construct by providing participants 199 
the opportunity to test procalcitonin on a smaller scale, develop experience, reflect on the 200 
intervention, suggest changes to improve the intervention and adaptation in the future. 201 
Participants provided specific examples of clinical situations where procalcitonin supported 202 
antimicrobial prescribing decisions along with examples of where it was considered of less 203 
benefit. Overall participants felt more confident in the role of procalcitonin in the acute 204 
infective setting and less confident in the reliability of procalcitonin in patients with 205 
underlying chronic lung disease. (Indicative quotations are shown in Table S1) 206 
Several elements of the ‘adaptable periphery’ [27] emerged which could be modified to 207 
improve the processing of samples in the laboratory and the subsequent availability of the 208 
procalcitonin results to clinicians. They included processing of the test more efficiently as part 209 
of a patients biochemistry profile by the biochemistry laboratory rather than processing 210 
samples in the microbiology laboratory (which occurred in this study). This would facilitate 211 
more prompt availability of results as part of the standard admission point of care blood test 212 
results. The changes suggested to the laboratory processing of the results were due to the 213 
elements of the intervention which aligned to the complexity construct and were considered 214 
barriers to implementation. (Indicative quotations are shown in Table S1) 215 
Participants commented positively on the education and training provided and were engaged 216 
with the intervention and its intended purpose of improving antimicrobial prescribing. 217 
(Indicative quotations are shown in Table S1) 218 
Participants suggested several other general recommendations to facilitate implementation 219 
of procalcitonin testing which aligned to the reflecting and evaluation construct. They 220 
included recommendations for a “multi-modal” educational plan, the need to identify the role 221 
of procalcitonin, “it’s place in the hierarchy” and to consider potential unintended 222 
consequences of its use. Participants also highlighted the need to gain support and 223 
endorsement from hospital management and senior clinicians and using public forums within 224 
the hospital such as “grand rounds” to facilitate this objective and engage champions 225 
(individuals) who actively associate themselves to support the intervention during 226 
implementation. 227 
Several potential barriers to implementation were also identified by participants. One 228 
participant highlighted that procalcitonin “has been around for quite some time” and 229 
questioned it’s relative advantage over C—reactive protein as an indicator of viral infections. 230 
The barrier of additional costs and availability of resources to support new interventions in 231 
the hospital means they would require “a really strong business case to suggest why we 232 
should add a resource”. The opportunity cost associated with implementing a procalcitonin 233 
intervention was also raised with the suggestion that alternative AMS interventions may be a 234 
more beneficial use of resources but this would require an economic assessment to 235 
determine the most cost-effective intervention..  236 
The respiratory specialist participants in the study expressed a strong sense of self-efficacy 237 
and confidence in their professional knowledge and clinical experience of treating respiratory 238 
tract infections and making antimicrobial prescribing decisions “it's very much linked to what 239 
we do”. They highlighted situations where they have come into conflict with the AMS team in 240 
relation to compliance with antimicrobial guidelines highlighting they “don’t inappropriately 241 
apply the guidelines as opposed to that we ignore them”. These findings were considered a 242 
potential barrier to implementation of AMS interventions.  243 
Theme 2: Antimicrobial stewardship and antimicrobial resistance context 244 
The need to address the problems associated with AMR were seen as facilitators to AMS 245 
interventions. Patient safety was seen as a priority but participants highlighted the increasing 246 
complexity and difficulties in managing patients with resistant infections. The management 247 
of patients with carbapenemase producing Enterobacteriaceae emerged as an example of the 248 
organisational approach to the problem of AMR and elements of this approach were 249 
considered as facilitators of implementation. The hospital “eventually” realised the problems 250 
associated with carbapenemase producing Enterobacteriaceae following communication 251 
between national and local level management resulting in greater leadership engagement at 252 
local level to address the problem. These factors created a tension for change to respond to 253 
this problem within the organisation and the need to take a long term rather than a short 254 
term view to respond to the problem. (Indicative quotations are shown in Table S2) 255 
The culture within the hospital in relation to antimicrobial prescribing emerged as a barrier 256 
to implementation of AMS interventions. The concepts of fear and risk aversion were a 257 
significant influence on antimicrobial prescribing decisions. Fear arose in relation to the 258 
“possibility of missing infection” in patients and the associated potential for negative clinical 259 
outcomes for those patients related to an inadequately treated infection and the associated 260 
feelings of clinical responsibility (indicative quotations are shown in Table S2). This fear was 261 
accompanied by the “fear of litigious issues” and the need for “self-protection”. Clinicians 262 
described the risk-aversion and need for self-protection as motivating factors for the 263 
prescription of antimicrobial courses to patients “even in times that maybe the front-line 264 
clinician themselves maybe isn’t convinced fully that it’s a bacterial infection”. There was 265 
acknowledgement of antimicrobial over-prescribing but these risks were outweighed by the 266 
needs of the individual complex sick patient admitted to hospital. A possible explanation for 267 
this which emerged was that the longer term consequences of AMR “aren’t as apparent” and 268 
may be perceived to be less important than the treatment of current patients. There was also 269 
an acknowledgement that the problem requires a significant amount of behavioural change 270 
as the “habits of the prescribing hand are firm and hard to change”. 271 
Theme 3: Hospital/organisational context 272 
All participants described a range of factors which act as barriers or facilitators of 273 
implementation. A growing culture of quality improvement in the hospital was described by 274 
all participants aligning with the culture construct. There were some differing individual 275 
perspectives on the degree of leadership engagement with quality improvement in the 276 
hospital with an acknowledgement that senior clinicians could be more engaged with it. The 277 
development of structural “scaffolding” to support a clinical lead with dedicated time to 278 
encourage and support quality improvement work was identified as a facilitator of future 279 
interventions. (Indicative quotations are shown in Table S3)    280 
Communication was seen as an important facilitator of interventions aligning with the 281 
networks and communication construct. The hospital size was seen as a positive factor to 282 
encourage greater engagement with colleagues. Communication between medical teams and 283 
the AMS team was seen as good and had a positive influence on antimicrobial prescribing. 284 
However inter-departmental communication, and communication between senior clinicians 285 
and hospital management emerged as a barrier to implementation. (Indicative quotations are 286 
shown in Table S3) 287 
Available resources emerged as a barrier to implementation in relation to the limitations of 288 
the funding model of Irish healthcare where despite the intensions of staff there is limited 289 
opportunities to “invest to get future success”. Participants also raised issues related to the 290 
perception of how resources are distributed within the hospital “it does seem to be he who 291 
shouts loudest”.  292 
Discussion 293 
This study provides a detailed PE of the introduction of procalcitonin testing as an AMS 294 
intervention. The CFIR guided a systematic assessment of the intervention and 295 
implementation process, identification of barriers and facilitators of implementation, and 296 
provided an insight into the contextual factors which influence AMS in the Irish hospital 297 
setting. The findings provide actionable recommendations to successfully implement a 298 
procalcitonin intervention. 299 
The main findings of this study identified the positive elements of the intervention and 300 
implementation process while also exploring the barriers to implementation related to the 301 
intervention and the contextual barriers of the study setting to be overcome to successfully 302 
implement a procalcitonin intervention. Participants engaged with the intervention, the 303 
education provided, assessed the supporting evidence for the intervention, gained 304 
experience of the intervention, reflected on its clinical value and proposed modifications to 305 
the intervention delivery which would improve implementation in a future randomised 306 
controlled trial. All these elements promote successful adaptation of interventions[27] and it 307 
has also been shown that previous experience of procalcitonin testing leads to greater 308 
confidence in the application of procalcitonin as an AMS intervention[31]. 309 
The adaptability and trialability constructs identified the most relevant factors to improve the 310 
delivery and selection of patients to maximise the benefits of the intervention. Procalcitonin 311 
levels were tested in the microbiology laboratory during this study and while the test itself 312 
was relatively quick to process there were several factors which led to delays in the availability 313 
of the results. These delays in availability resulted in clinicians feeling that “hearing 314 
afterwards it was something that you know, you felt almost it was a feedback after the 315 
decision had been made” rather than contributing to the clinical decision-making process. 316 
Processing of the procalcitonin level in the biochemistry laboratory emerged as a solution to 317 
this problem and the procalcitonin levels should be available as part of the admission list of 318 
blood results at the point of care to allow the results to be “more of a clinical influence” on 319 
prescribing.  320 
The participating respiratory clinicians expressed a strong degree of self-efficacy in relation 321 
to their expert knowledge and clinical experience in treating respiratory tract infections while 322 
also acknowledging the diagnostic difficulties associated with respiratory tract infections. 323 
These findings suggest that respiratory clinicians could be perceived as barriers to 324 
implementation of AMS interventions and are similar to those found in a recent study which 325 
highlighted the barriers to integrating AMS processes within respiratory medicine[32]. The 326 
perception that unsolicited AMS input is considered an imposition on specialist territory and 327 
clinical autonomy among some medical specialists who consider themselves ‘experts in their 328 
own fields’ is a considerable barrier to AMS interventions[33].  329 
One clinician highlighted that procalcitonin “has been around for quite some time’ and 330 
questioned it’s relative advantage over other infection markers. However most participants 331 
viewed the intervention positively which suggests that procalcitonin is a potentially effective 332 
intervention as it combines clinician enablement, improved diagnostics to support AMS but 333 
requires engagement with clinicians to optimise effectiveness. An intervention of this nature 334 
would fulfil the recommendations of a recent study[34] to overcome barriers in AMS in 335 
respiratory medicine. These findings align with a qualitative study of clinicians experience 336 
with procalcitonin where the intervention was viewed positively as an AMS adjunct but it 337 
could not replace other tests or clinical judgement[35].  338 
The CFIR provided a framework to explore the two main contextual factors of AMS and the 339 
hospital/organisational context into which the intervention was introduced. Contextual 340 
factors influencing AMS interventions have been poorly explored in the past[6] and a lack of 341 
understanding of the contextual factors contributing to a given problem can lead to sub-342 
optimal implementation[36].  343 
The concepts of fear and risk-aversion were prominent themes in the AMS/AMR context. The 344 
care of their patients and patient safety is the primary concern for clinicians[37]. Patients 345 
admitted to hospital with a suspected infection are perceived to be more “complex” and 346 
“sick” which heightens the fear of missing an infection and the potentially serious outcomes 347 
for patients including death which heavily influences antimicrobial prescribing decisions. Fear 348 
of adverse clinical outcomes especially in hospital patients has a powerful influence on 349 
antimicrobial prescribing which can escalate the risk perception of clinicians[33]. Clinicians 350 
were risk-averse even in situations where the risk of a bacterial infection is low “I think a lot 351 
of people will still cover with antibiotics”. Clinicians also cited concerns on a personnel level 352 
perceiving a need for self-protection and a fear of litigation which results in the prescription 353 
of antimicrobials “just in case”. Justification of the fear of litigation may be due to the fact 354 
that medical negligence suits filed in the Irish High court have increased by 136% from 2007 355 
and 2018[38] and clinical negligence claims against the NHS in the UK have doubled over a 356 
similar period[39]. In the ever-increasing litigious world we live in, this is a significant barrier 357 
going forward.  358 
The findings demonstrate that clinicians consider the short terms risks to patients and 359 
themselves more heavily than the longer term consequences of AMR which “aren’t as 360 
apparent” when making antimicrobial prescribing decisions similar to the findings of a recent 361 
systematic review[40]. Risk, real or perceived, is challenging to mitigate against. AMS 362 
programmes must acknowledge the experiences of risk faced by clinicians when designing 363 
AMS interventions. An intervention such as procalcitonin acting as an “extra marker” of the 364 
infection process offers clinicians further information when making antimicrobial prescribing 365 
decisions potentially reducing the perceived risks for both patient and clinician.  366 
The hospital context consisted of both barriers and facilitators to implementation. The 367 
hospital administrator highlighted the recognition of the problems associated with AMR 368 
having gained greater insight during the hospitals response to a carbapenemase producing 369 
Enterobacteriaceae outbreak and the significant costs associated with it. Unfortunately the 370 
realities of managing limited resources in a hospital environment where the short term 371 
demands of trying to “push people through the system” is difficult and limits the ability of 372 
hospitals to invest in new interventions or diagnostics to mitigate the long-term 373 
consequences of AMR. These findings are similar to the findings of another study investigating 374 
the perspective of hospital managers on optimising antimicrobial use[41]. A medical 375 
laboratory scientist expressed frustration with the economic constraints of the healthcare 376 
system where it appears that resources are allocated to “he who shouts loudest”. In the 377 
current setting of a resource limited health service new interventions such as procalcitonin 378 
must be supported by “a really strong business case” and an economic evaluation of the 379 
intervention should be incorporated into a future trial particularly in the Irish hospital setting. 380 
Procalcitonin testing has been shown to be a cost-effective AMS intervention in the U.S. 381 
setting[42] but the overuse of procalcitonin testing has also been highlighted[43]. Long term 382 
investment in the health system is necessary to alter the realities of AMR. This is particularly 383 
important given our current population demographic in Ireland where the proportion of the 384 
population over 65 years is expected to increase to 1.6 million in the next 35 years[44]. 385 
Positive findings from the hospital context included the recognition of developing a culture 386 
of quality improvement in the hospital. Additional resources and support are required to 387 
develop the “scaffolding” within the hospital but this is an important facilitator for the 388 
development of new interventions. We know from previous work that organisations which 389 
have a patient centred culture are more likely to implement change effectively[45]. 390 
Communications within an organisation has been recognised as being important in 391 
intervention implementation. There was some variation in the assessment of it in the hospital 392 
context and both positive and negative aspects were identified. The small size of the hospital 393 
was noted as having a beneficial effect on communication in this study. Implementation has 394 
been described as a ‘social process’ which is intertwined with the context in which it takes 395 
place[46]. The importance of factors such as gaining “consultant buy-in” and using 396 
educational forums such as grand rounds to encourage engagement and discussion of 397 
interventions by senior clinicians are noted. 398 
Strengths and limitations 399 
The findings of this study and our earlier quantitative work[19] support the finding that 400 
procalcitonin is an effective intervention and thus support the recommendations to link the 401 
CFIR constructs to intervention outcomes[13]. We have outlined the justification for our 402 
choice of the CFIR[13]. The study included a broad range of participants not just those directly 403 
involved in the study implementation. 404 
The study had several limitations. The study took place in a single hospital setting and 405 
contextual influences may differ in other hospitals and this may limit its transferability. 406 
However, as this is a feasibility study, this could not be mitigated for in this instance. Only one 407 
hospital administrator was interviewed which limits the insight from the administrative 408 
perspective on the hospital context. However due to the single study site it was only possible 409 
to interview one administrator who would have the knowledge to provide these details. The 410 
feasibility study and PE were conducted by the same researchers increasing the risk of positive 411 
reporting. There was also a risk of the hawthorn effect during the data collection process as 412 
it is possible the interviewer could have influenced the way people behave or respond. Efforts 413 
to avoid or minimise bias and the hawthorn effect included purposive sampling and inclusion 414 
of a diverse sample of individuals.   415 
Conclusion 416 
This PE provides a detailed qualitative analysis of the implementation of procalcitonin testing 417 
as an AMS intervention. Positive elements of intervention implementation were highlighted 418 
along with modifications to improve the delivery of the intervention such as the prompt 419 
availability of procalcitonin levels at the point of care to allow the test to be “more of a clinical 420 
influence” on prescribing. Contextual factors which influence implementation were identified 421 
and explored including the concepts of fear, risk and the influence of respiratory clinicians on 422 
AMS interventions. We would recommend that the positive findings of this PE and feasibility 423 
study should be built upon and that a full randomised controlled trial and economic 424 
evaluation should be conducted in a variety of hospital settings to confirm the effectiveness 425 
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Table 1. Health professionals` role during the procalcitonin implementation 556 
Health professional Role in implementation 
Hospital administrator Hospital-wide managerial responsibilities and oversight of funding 
decisions 
Respiratory clinicians Involved in the procalcitonin intervention implementation and 
assessment 
Clinicians Provided insight into the contextual elements of implementation 
Medical laboratory scientists Laboratory processing of the procalcitonin tests 
  557 
Table 2. Consolidated framework for implementation research domains and constructs 558 
associated with qualitative themes 559 
Theme CFIR  domains CFIR  constructs 




Evidence strength and quality, Relative 
advantage, Adaptability, Trialability, 
Complexity, Design quality and packaging, 
Costs (opportunity) 







resistance  context 
Outer setting 
 
Patient needs and resources, 
Cosmopolitanism, External policy and 
incentives 
Inner setting Culture, Tension for change, Relative 




Inner setting Structural characteristics, Networks and 
communications, Culture, Leadership 
engagement 
Process Champions, Available resources 
 560 
